How tiny cell pockets (caveolae) help the eye drain fluid and control pressure
Caveolae-Based Mechanosensors for Conventional Outflow Regulation
This work looks at whether small cell structures called caveolae help the eye's drainage system keep eye pressure normal for people with or at risk for primary open-angle glaucoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11302688 on NIH RePORTER |
What this research studies
Researchers will study how caveolae in the drainage tissues of the eye (trabecular meshwork, Schlemm's canal, and downstream vessels) respond when eye pressure changes. They will combine cell and animal experiments with human genetic findings linking CAV1/2 genes to glaucoma to see how loss or alteration of these proteins affects fluid outflow and pressure. The team will remove or alter the CAV1 gene in specific outflow cells to measure effects on aqueous humor drainage and intraocular pressure. The goal is to map the signaling and mechanical steps that let caveolae protect the drainage pathway and suggest targets for new treatments.
Who could benefit from this research
Good fit: People with primary open-angle glaucoma, ocular hypertension, or those with a family history or known CAV1/CAV2 gene variants would be most relevant for this line of research.
Not a fit: People with glaucoma types not caused by conventional outflow dysfunction (for example, primary angle-closure glaucoma) or whose eye pressure is already well controlled may not benefit directly.
Why it matters
Potential benefit: If successful, this work could point to new ways to lower or stabilize eye pressure by targeting caveolae-related pathways, potentially preventing vision loss from glaucoma.
How similar studies have performed: Previous human genetics work has linked CAV1/2 to glaucoma and animal or cell experiments show CAV1 loss raises eye pressure, but translating these findings into treatments is still novel and unproven.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Elliott, Michael H — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Elliott, Michael H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.